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ABSTRACT
Introduction: Breast cancer represents about one-
third of all cancer diagnoses and accounts for about
15% of cancer deaths in women. Many of these
patients experience depression, anxiety, sleep
disturbances and cognitive dysfunction. This may
adversely affect quality of life and also contribute to
morbidity and mortality. Melatonin is a regulatory
circadian hormone having, among others, a hypnotic
and an antidepressive effect. It has very low toxicity
and very few adverse effects compared with the more
commonly used antidepressants and hypnotics.
Methods and analysis: The objective of this double-
blind, randomised, placebo-controlled trial is to
investigate whether treatment with oral melatonin has
a prophylactic or ameliorating effect on depressive
symptoms, anxiety, sleep disturbances and cognitive
dysfunction in women with breast cancer.
Furthermore, the authors will examine whether
a speciﬁc clock-gene, PER3, is correlated with an
increased risk of depressive symptoms, sleep
disturbances or cognitive dysfunction. The MELODY
trial is a prospective double-blinded, randomised,
placebo-controlled trial in which the authors intend to
include 260 patients. The primary outcome is
depressive symptoms measured by the Major
Depression Inventory. The secondary outcomes are
anxiety measured by a Visual Analogue Scale, total
sleep time, sleep efﬁciency, sleep latency and periods
awake measured by actigraphy and changes in
cognitive function measured by a neuropsychological
test battery. Tertiary outcomes are fatigue, pain, well-
being and sleep quality/quantity measured by Visual
Analogue Scale and sleep diary and sleepiness
measured by the Karolinska Sleepiness Scale. The
PER3 genotype is also to be determined in blood
samples.
INTRODUCTION
Breast cancer is the most common type of
cancer among women worldwide with about
1.4 million new cases every year.
1 Breast
cancer accounts for 31% of the various cancer
diagnoses in women and is responsible for
15% of deaths in women due to cancer.
2 For
Danish women, it is the most common type of
cancer and the incidence is rising.
3 The inci-
dence rises towards the age of 65 and then the
curve ﬂattens out.
3 Improvement of treat-
ment has led to increasing 5-year survival,
which is now 84% in Denmark
4 and 89% in
the USA.
5 Now focus has turned to optimising
quality of life because these patients may have
a number of different psychological and
physical symptoms, such as depression,
anxiety, fatigue, cognitive dysfunction and
sleep disturbances.
6e12
METHODS
Study design and objectives
MELODY (The effect of MELatOnin on
Depression, anxietY, cognitive function and
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Open Access Protocolsleep disturbances in breast cancer patients) is a prospec-
tive double-blinded, randomised, placebo-controlled trial
in which we intend to include 260 patients undergoing
surgery for breast cancer at Herlev University Hospital in
Copenhagen, Denmark. If target sample size is not being
adequately achieved, other centres/hospitals in Denmark
will be invited to participate.
The objective is to investigate whether treatment with
oral melatonin has a prophylactic or ameliorating effect
on depressive symptoms, anxiety, sleep disturbances and
cognitive dysfunction in women with breast cancer.
Furthermore, we will examine whether a speciﬁc clock-
gene, PER3, is correlated with an increased risk of
depressive symptoms, sleep disturbances or cognitive
dysfunction.
Patients in the intervention group will receive 6 mg
oral melatonin daily 1 h before bedtime for 1 week
preoperatively to 12 weeks postoperatively. Patients in
the control group will receive placebo.
The melatonin/placebo will be supplied from Pharma
Nord ApS (Vejle, Denmark), and the tablets (melatonin/
placebo) are physically identical.
Study population
Approximately 1 week preoperatively patients are indi-
vidually assessed and screened for inclusion (table 1). This
includes a Mini Mental State Examination, a neuropsy-
chological test with the ISPOCD test battery
13 and the
Major Depression Inventory (MDI).
14e16 Hereafter,
patients will on a daily basis ﬁll out Visual Analogue Scales
(VAS) regarding anxiety, fatigue, pain, general well-being
and sleep, complete a sleep diary and ﬁll out the Karo-
linska Sleepiness Scale (KSS). An Actigraph will be
mounted on the wrist and worn continuously until
2 weeks postoperatively. Patients will be randomised to
either 6 mg melatonin or placebo. Patients will be
instructed to take their medicine every evening at
21:00e22:00 and continue with this for 13 weeks. A blood
sample will be collected for the analysis of PER3 genotype.
A visit is scheduled 2 weeks postoperatively where
patients are tested with the ISPOCD test battery and the
MDI. At this time, the Actigraph will be taken off.
During the last 10 weeks of the study, patients will be
assessed with the MDI twice and every 2 weeks ﬁll out
VAS regarding anxiety, fatigue, pain, general well-being
and sleep, complete a sleep diary and ﬁll out the KSS.
At the ﬁnal visit, 12 weeks postoperatively patients will
be tested with the ISPOCD test battery and the MDI.
To ensure compliance and promote participant
retention and follow-up, patients will throughout the
whole study period of 13 weeks be contacted by tele-
phone seven times to remind them to ﬁll out VAS, sleep
diary, KSS and MDI at appropriate times, to remind
them to take their tablets daily, to ask about adverse
reactions and to ask about diagnosis of depression since
the last contact.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
< Women between 30 and 75 years
< Lumpectomy or mastectomy
< American Society of Anesthesiologists
(ASA) classes IeIII
< No sign of depression on Major Depression
Inventory (MDI)
< Not pregnant
< Neoadjuvant chemotherapy
< Treatment with:
– Selective serotonin reuptake inhibitors
– Antithrombotic drug therapy (except 75 mg acetylsalicylic
acid daily)
– Monoaminoxidase (MAO) inhibitors
– Calcium channel blockers
< Rotor or DubineJohnson syndrome
< Epilepsy
< Known allergic reaction to melatonin
< Known and treated sleep apnoea
< Diabetes mellitus treated with insulin
< Ongoing or previous medically treated depression or bipolar disorder
< Known autoimmune diseases (systemic lupus erythematosus,
rheumatoid arthritis or multiple sclerosis)
< Incompensated liver cirrhosis
< Severe kidney disease (receiving dialysis)
< Previous or other current cancer
< Known medically treated sleep disorder (insomnia, restless legs, etc)
< Shift work or night work
< Daily intake of >5 units (1 unit ¼8 g pure alcohol)
< Preoperative, continuous treatment with psychopharmacological
drugs of any kind, opioids, anxiolytics or hypnotics
< Predicted poor compliance
< Breast feeding
< Preoperative Mini Mental State Examination score <24
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During the trial, patients who experience serious peri- or
postoperative complications/events causing unexpected
morbidity or pain during the ﬁrst postoperative days (ie,
cardiopulmonary complications (myocardial infarction,
serious arrhythmia, pulmonary oedema), thromboem-
bolic complications (deep venous thrombosis, pulmo-
nary embolism) and wound infection (with fever and
elevated white blood cells and C reactive protein)), will
be excluded. No further data will be collected on these
patients after they are excluded; previously collected
data will not be analysed, and the patients will not
continue the trial medication.
The goal with medicine compliance is a minimum of
75% compliance in the ﬁrst 3 weeks and 50% for the rest
of the study period. Patients will be excluded if they at
the visit 2 weeks postoperatively have not taken at least
75% of the study medication. No further data will be
collected and the patients will not continue the trial
medication. Patients who have not taken at least 50% of
the trial medication at the last visit will not be analysed
on the long-term effect variables. Patients will be
instructed to bring all the study medication (open and
closed blister packets) with them at every visit to control
compliance.
All potential, included and randomised patients will
be accounted for in a screening log, in an identiﬁcation
list, in the CONSORT trial proﬁle and in a baseline data
table.
Randomisation
Patients who have provided written and informed
consent preceding inclusion and who meet all the
inclusion criteria and none of the exclusion criteria are
randomised to either melatonin 6 mg or placebo. Inclu-
sion and randomisation is done 1 week preoperatively.
The randomisation is based on blocks of six. The
randomisation list is computer generated using dedi-
cated software (http://www.randomization.com). To
ensure that the randomisation list is not known to the
investigator, this procedure is completed by the phar-
macy who receives the medicine directly from Pharma
Nord ApS. In case of dropouts leading to <120 patients
in each group, the study will include new blocks of six
patients to ensure randomisation and balance between
the two groups.
Data and adverse events
Data are collected on individual paper case report forms
(CRFs), and data will be stored for 15 years and then
destroyed. Data from these CRFs will be transferred as
double data entry to a database. In this database,
patients are coded with a patient number and the data-
base is saved on the hospitals computer server to ensure
maximum security. Spot checks to validate data transfer
from the CRFs to the electronic database will be
completed by the Good Clinical Practice Unit.
Due to melatonins relative non-toxicity shown in both
animal and human studies and due to the fact that
prolonged treatment with melatonin or melatonin
receptor agonists have not shown any serious adverse
effects, no Data Monitoring Committee is initiated and
no interim analyses have been planned in the course of
the study.
Throughout the trial, both the sponsor/investigator,
who informs the patient and the patient herself, will be
blinded. A code breach will occur if an unexpected event
arises in relation to the surgical procedure and/or the
postoperative period where there is a reasonable prob-
ability of an adverse reaction. Unexpected events do not
include procedure-related surgical/medical/anaesthetic
complications. Code breach is possible without prior
contact to sponsor/investigator. The risk of early trial
termination is not existent.
The summary of product characteristics for melatonin
will be used as a reference document. The following
known, usual side effects (1%e10%) and non-usual side
effects (0.1%e1%) will not be registered as adverse
events: light headache, light nausea, dyspepsia, minor
symptoms of sleepiness and light morning drowsiness.
Furthermore, complications in relation to surgery will
neither be registered as adverse events.
All adverse events will be registered and reported to
the Danish Medicines Agency and the local ethics
committee in the ﬁnal report. All serious adverse events
will be reported to the local ethics committee in an
annual report together with a report on patient safety.
All serious adverse reactions will be reported to the
Danish Medicines Agency in an annual report together
with a report on patient safety. The summary of product
characteristics for melatonin will be used to judge
whether a serious adverse reaction is expected/unex-
pected and thereby a possible sudden unexpected
serious adverse reaction. The sponsor/investigator will
make sure that all information about sudden unex-
pected serious adverse reactions, that are lethal or life
threatening, will be registered and reported to the
Danish Medicines Agency as soon as possible and at the
latest 7 days after sponsor/investigator has received
knowledge of such a reaction. At the latest 8 days after
this reporting, sponsor/investigator will inform the
Danish Medicines Agency of the follow-up. All other
sudden unexpected serious adverse reactions will be
reported to the Danish Medicines Agency at the latest
15 days after sponsor/investigator has gained knowledge
of these. In these situations, the patient will be followed
until the reaction has terminateddeither via contact
with the sponsor/investigator or via the outpatient clinic
at the hospital.
Melatonin
Melatonin is a hormone that is produced at night in the
corpus pineale in a rhythmical pattern and controlled by
an endogenous clock in the suprachiasmatic nucleus of
the hypothalamus.
17 Its main function is to synchronise
the circadian rhythm.
17 Melatonin is mostly known for its
role as a circadian hormone, but it also has known
sedative,
18 19 anxiolytic,
18 19 analgesic,
20 21
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22 23 non-inﬂammatory
24 and onco-
static effects.
25e27 Melatonin has a possible anti-
depressive effect
28e34 probably based on its effect on the
central circadian regulation
35 and an effect on
improving cognitive function.
36 Figure 1 shows the
complexity of the relationship between breast cancer
and depression and the possible attack points of mela-
tonin.
The secretion rhythm, ﬂuctuations and levels of
melatonin have been previously investigated with regard
to surgery, depression and also breast cancer. After
surgery, melatonin secretion has shown to be acutely
disturbed
37 with a delay of secretion and reduced
amplitude.
38 39 Various lines of evidence show that
depressed patients exhibit disturbances in both the
amplitude and the shape of the melatonin secretion
rhythm, with some studies showing a low nocturnal
melatonin secretion and others showing an increase in
secretion.
35 A growing amount of evidence from
prospective studies suggests an association between
night work and breast cancer risk, most likely due to
subsequent melatonin suppression.
40
Melatonin is relatively non-toxic.
41e43 Animal studies
have shown that the maximum dose given in vivo,
without any adverse effects or death, is 200 mg/kg for
pregnant rats throughout the whole pregnancy and
800 mg/kg for mice.
44 45 The drug has been used in
many clinical studies of both adults
18e20 22 41 42 46 47 and
newborns
48 49 without serious adverse effects. Doses of
1000 mg daily for 1 month have been given, and the only
reported adverse effect was drowsiness.
41 In a recent
systematic review, the most often reported side effects
were headache, dizziness, nausea and drowsiness.
50
PER3 clock-gene
Previous studies have shown that certain genes, called
clock-genes, have a role in regulating circadian rhythms
and sleep in humans.
51 A coding region in the clock-
gene PER3, which is repeated in either 4 or 5 units, has
been coupled to various phenotypical traits, A or B
people, sleep diseases,
52e54 affective disorders,
55 56
cognitive function after sleep deprivation,
54 57 and in
one study,
58 a relationship was found between the 5/5 og
4/5 genotype of the PER3 gene and breast cancer. We
would like to investigate whether sleep quality, cognitive
function or depressive symptoms are correlated with any
of these three PER3 genotypes.
Ethics
The study will be performed in agreement with the
Helsinki II declaration and law 503 of 1992 about the
Scientiﬁc Ethics Committee System and is approved by
the local ethics committee (H-4-2011-007). The study has
also been approved by the Danish Medicines Agency
(EudraCT nr. 2010-022460-12) and the Danish Data
Protection Agency (2007-58-0015/HEH.750.89-12). The
project is registered on http://www.clinicaltrials.gov as
recommended by the International Committee of
Medical Journal Editorsdclinicaltrials.gov identiﬁer:
NCT01355523. The Good Clinical Practice Unit at
Copenhagen University will oversee the trial and
conduct trial audit periodically.
All authors will have direct access to data during and
after the trial. Furthermore, the sponsor/investigator
will allow direct access to source data/documents,
including patient charts, at monitoring, audit and/or
inspection from the Danish Medicines Agency, the Good
Clinical Practice Unit or from health authorities from
other countries.
EFFECT PARAMETERS
Major Depression Inventory
The primary, secondary and tertiary effect parameters of
the trial can be seen in table 2. Major Depression
Inventory (MDI) is a self-rating scale including 12
questions. The questionnaire is already well documented
in a Danish population.
14 The questions cover the 10
ICD-10 questions for depression, and the symptoms are
identical with the DSM-IV major depression diagnosis
apart from one symptom, low self-esteem (question 4),
which in DSM-IV is incorporated in the question about
guilt (question 5). The MDI includes 10 items, where
Figure 1 The relationship
between breast cancer and
depression. Modiﬁed after
Fann et al.
6
Primary therapy Cognitive function
BREAST
CANCER
DEPRESSION
Physical functioning Psychosocial factors
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b. For items 8 and 10, the highest score of questions
a and b is included. The individual items are measured
on a 6-point Likert scale with graduations depending on
the extent of the symptom the last 14 days, 0 (the
symptom has not been present) till 5 (the symptom has
been present continuously).
The MDI has a dual function. It can be used as
a diagnostic tool where it can, by algorithms, lead to
either DSM-IV or ICD-10 categories of ‘major’ or
‘moderate to severe depression’. An acceptable sensi-
tivity and speciﬁcity for the diagnosis of depression
according to ICD-10 and DSM-III/DSM-IV has previously
been found.
15 The MDI can also be used as a measuring
instrument to indicate the severity of the depression.
Thus, the MDI correlates with the Hamiltons Depres-
sions Scale (HAM-D).
16
Actigraphy
Actigraphy is a well-known, non-invasive method to
objectively measure sleep. Using an actigraph, activity
levels are registered by a wrist-worn mini-computer. This
method which does not disturb the patients’ sleep has
been used for many years
59 and also in the postoperative
setting.
60 It has been shown that actigraphy has a high
sensitivity and speciﬁcity for detecting sleep start, sleep
periods and awakenings.
59 The gold standard for
measuring sleep is polysomnography. Actigraphy has
a high speciﬁcity for detecting whether the patient is
asleep or awake but cannot differentiate between sleep
stages and score REM sleep.
An actigraph measures small accelerations with a piezo-
electrode and stores this in an internal memory. Data can
be recorded via different modalities, and we will be using
the zero crossing method, where all acce-
lerations (>0.1G), which cross a certain threshold (0 or
very close to 0), will be detected. The sleep analysis will be
performed by dedicated software (Action4 software;
Ambulatory Monitoring Inc., New York, New
York, USA) by using the ColeeKripke algorithm.
61
Data will be reported as total sleep time per period, sleep
efﬁciency, sleep ratio, number of awakenings
and duration of awakenings. The method is validated and
has been used previously to measure sleep in patients
with breast cancer before, during and after surgery.
62e65
The ISPOCD neuropsychological test battery
The cognitive function of the patients will be tested
preoperatively and at 2 weeks and 3 months post-
operatively. The test battery consists of four validated
tests: the Visual Verbal Learning Test, the Stroop Colour-
Word Test, the Letter-Digit Coding Test and the Concept
Shifting Task.
The test battery takes approximately 45 min to
complete and has been used previously in the large
multicenter ISPOCD trial.
13
Anxiety and sleep quality measurements
A subjective feeling of anxiety will be registered on a VAS
going from ‘no anxiety’ to ‘worst possible anxiety’.
Measurements will take place daily for the ﬁrst 3 weeks of
the study and every 2 weeks for the last 10 weeks.
Subjective sleep quality will be registered on a VAS
going from ‘best possible sleep’ equivalent to 0 mm to
‘worst possible sleep’ equivalent to 100 mm. Patients will
also ﬁll out VAS regarding general well-being, fatigue
and pain. Measurements will take place at the same time
as for anxiety.
Furthermore, a sleep diary, recording sleep time and
awakening time, will be completed daily for the ﬁrst
3 weeks of the study and thereafter every 14 days. Patients
will at the same time periods complete the KSS, which is
used to quantify levels of sleepiness. KSS is a 9-point scale
from 1 (very awake) to 9 (very sleepy), where a score of 7
or more reﬂects pathological sleepiness.
66
Other collected data
Age, weight, height, menopausal status, educational
level, cohabitation status, work market afﬁliation,
household income, number of children/number of
children living at home, smoking habits, American
Society of Anesthesiologists (ASA) class, duration of
surgery, the size of the incision, consumption of anal-
gesics postoperatively and which postoperative oncolog-
ical treatment each patient receives after surgery.
STATISTICAL ANALYSIS AND SAMPLE SIZE CALCULATION
The sample size estimation is based on a conservative
estimate of the incidence of depression of 30% in breast
cancer patients
7 with a reduction to 15% with melatonin
treatment. With a power of 80%, a risk of type I error of
Table 2 Effect parameters
Primary effect parameter Secondary effect parameters Tertiary effect parameters
< Major Depression
Inventory
< Anxiety measured by Visual Analogue
Scale (VAS)
< Total sleep time, sleep efﬁciency, sleep
latency and periods awake measured by
actigraphy
< Changes in cognitive function measured
by a neuropsychological test battery
< PER3 genotype correlated with sleep,
cognitive function and depressive symptoms
< Fatigue, pain, well-being and sleep
quality/quantity measured by VAS
< Sleep diary
< Sleepiness measured by the Karolinska
Sleepiness Scale
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include 120 patients in each group receiving melatonin
or placebo. We have chosen to include 130 patients in
each group. Statistical analyses will be done using SPSS
V.18.0.
Regarding our primary outcome mean MDI total
scores and prevalences of ICD-10 mild, moderate and
severe depression will be calculated for both sam-
ples. Normality of the data will be tested by one
sample KolmogoroveSmirnov test and parametric or
non-parametric statistics will be used accordingly. The
two groups will be compared by Fisher’s exact test for the
primary outcome. Paired Student t test or Wilcoxon test
will be used for intragroup comparisons and unpaired
Student t test or ManneWhitney’s test for intergroup
comparisons. For repeated measures, Friedman test or
an analysis of variance will be used when appropriate.
For comparing anxiety by VAS and sleep architecture
(objective data from the actigraph), we will do intergroup
comparisons with ManneWhitney’s test and intragroup
comparisons using the Wilcoxon signed-rank test.
For analysing postoperative cognitive dysfunction
(POCD) in the two groups, we will use 232 tables and
a Fisher’s exact test. Patients will be deﬁned as having
POCD if two of the seven Z-scores in individual test or
the combined Z-score are $1.96.
13 Analysis of variance
will be used to analyse the two groups and the speciﬁc Z-
scores for the seven subtests and the combined Z-scores.
A Bonferroni correction will be made when performing
multiple comparisons.
For analyses of correlation between PER3 genotype
and sleep, cognitive function and depressive symptoms,
a logistic regression analysis will be used. For the
subjective parameters fatigue, pain, general well-being
and sleep quality/quantity measured by VAS and sleep-
iness by KSS, we will do intergroup comparisons with the
ManneWhitney test and intragroup comparisons using
the Wilcoxon signed-rank test. We plan to do intention-
to-treat as well as per protocol analyses. In general,
p<0.05 will be considered statistically signiﬁcant.
DISCUSSION
There is a complex relationship between depression and
breast cancer with inﬂuence from various factors (ﬁgure
1). Due to the high frequencies of depression, anxiety,
sleep disturbances and cognitive dysfunction in patients
with breast cancer, a high interest is found in preventing
these co-morbid symptoms.
Depression is both underdiagnosed and undertreated
in many cancer patients,
11 67 especially those with breast
cancer.
68 The overall rate of depression in patients with
breast cancer is higher than in most cancers. This is most
likely because menopause, either naturally occurring or
premature due to the effects of chemotherapy and/or
anti-hormone treatment, and oestrogen decline are
related to depression.
6 It has been shown that up to 50%
of patients with breast cancer may experience depression
and/or anxiety within the ﬁrst year of diagnosis.
7
Concomitant breast cancer and depression is associated
with higher mortality and morbidity
67 69e72 and also
lower patient satisfaction
73 and compliance to adjuvant
therapy
74 and general medical treatment.
75 Even a year
after surgery, many women still deal with an anxiety
problem
76 and about 15% are still depressed.
7
Studies have shown that treating anxiety and depres-
sion in these patients with breast cancer improves their
quality of life, leads to a higher completion of adjuvant
therapy and extends their lifetime.
68 77 78 Therefore, it is
important to optimise the treatment of these symptoms.
A number of randomised, controlled trials have
examined the efﬁcacy of antidepressants compared with
placebo in patients with breast cancer.
78e85 A high
number of dropouts due to side effects related to the
antidepressant treatment have also rendered such trials
difﬁcult to complete.
79 84 86 Furthermore, recent
evidence indicates that some selective serotonin reup-
take inhibitor antidepressants may reduce tamoxifen’s
effectiveness and are associated with an increased risk of
mortality.
87 88
Sleep disturbances are a frequent problem in cancer
patients.
89 90 Compared with other types of cancer,
breast cancer is associated with an exceptionally high
rate of reduced sleep quality
10 89 which can be found
even many years after end of treatment.
8 The estimated
prevalence of sleep problems among patients with breast
cancer is between 38% and 61%,
10 89 91 92 and it may
reduce quality of life in this group of patients.
91 93 About
30% of patients with breast cancer take hypnotics
10 89 92
leading to a potential dependency problem and it is
therefore important to focus on treatments with less
adverse effects.
The sleep disturbances can be due to a variety of
factors, both physical and psychological, which all have
a mutual inﬂuence on each other. Among the psycho-
logical factors, depression and anxiety are well known,
and these patients also exhibit a change in sleep archi-
tecture.
94 In general, depressed patients display sleep
abnormalities such as difﬁculties falling asleep and
staying asleep, lose of slow-wave-sleep and changed
REM sleep.
95 Pain and hot ﬂushes are examples of the
physical factors.
89 19 2
Overall, it is difﬁcult to conclude whether sleep
disturbances are a precursor or a sequelae of depression.
Various studies in healthy individuals have shown
a causal relationship between sleep disturbances and the
following development of depression.
96 97 More speciﬁ-
cally for patients with breast cancer, a circadian rhythm
disruption has been associated with depression, fatigue
and pain.
62 63 65 98 Altogether, there is a complicated
relationship between circadian disturbances, sleep and
mood,
35 and this is especially prevalent in patients with
breast cancer.
99
Disturbances of cognitive function are a prevalent
phenomenon in patients with breast cancer and can
inﬂuence the general quality of life in this group of
patients.
9 12 Studies have suggested that the cancer per
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chemotherapy and hormone therapy or genetics can be
contributing factors in the development of cognitive
disturbances.
100 101 POCD is characterised by a deterio-
ration in memory, concentration and information
assessment after surgery.
13
In other settings, some studies have shown that mela-
tonin can attenuate cognitive dysfunction,
36 102 103 and
this mechanism together with the general improvement
of sleep could be beneﬁcial on cognitive disturbances in
this speciﬁc group of patients. Since there is no speciﬁc
knowledge on this topic with regard to breast cancer, it is
necessary to investigate whether the development of
cognitive problems can be prevented by melatonin
treatment.
In conclusion, we hope, with this project, to decrease
the occurrence of depression, anxiety, sleep disturbances
and cognitive dysfunction in patients with breast cancer
and in a larger perspective reduce morbidity and
mortality and improve quality of life for these patients.
With regard to genetics, this project could lead to the
possibility of being able to detect women with a higher
risk of developing the above mentioned problems and
then give indication for selective prophylactic treatment.
The diversity of melatonin’s physiological functions and
treatment effects are continuously being investigated in
both animal and human studies. To date, the effect of
melatonin in a breast cancer population with the above-
mentioned indications has not yet been studied.
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